ABA Home
Patent Law

Plavix Patent Upheld

Posted Jun 19, 2007, 12:52 pm CDT
By Debra Cassens Weiss

A federal judge in Manhattan today upheld a patent on the blood thinner Plavix.

U.S. District Judge Sidney Stein said Plavix’s maker, Sanofi-Aventis, was entitled to an injunction barring a competitor's generic version of the drug for four years, the Wall Street Journal reports.

Apotex Inc. had sought to invalidate the Plavix patent, arguing it was anticipated in an earlier patent filing.

Plavix is marketed by Sanofi and Bristol-Myers Squibb Co.

On June 11, Bristol-Myers agreed to pay a $1 million fine for making false statements to the Federal Trade Commission about a former executive’s discussions with Apotex about a proposed settlement of the case.

The executive’s remarks were intended to lead Apotex to conclude that Bristol-Myers would refrain from launching a generic version of the drug if the parties reached a revised settlement, according to a Justice Department press release.

The fine resolves an antitrust investigation.

E-Mail This Story


(Separate multiple addresses with a comma.)




Share This Story

URL to share: http://www.abajournal.com/news/plavix_patent_upheld/

Title: Plavix Patent Upheld


Comments

    Be the first to comment.


Commenting has expired on this post.


Subscribe

Get the ABA Journal the way you want it — in print, online, by e-mail — and when you want it — monthly, weekly, daily or as news breaks.





Are you an ABA Member? Read This First

Subscribe via RSS
Subscribe to the mobile edition
Subscribe to the monthly magazine


Return to top